P/E ratio for AstraZeneca (AZN)

P/E ratio history for AstraZeneca from 2009 to 2026

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	26.5	-0.89%	🇺🇸 USA
Novartis NVS	21.5	-19.41%	🇨🇭 Switzerland
Pfizer PFE	20.0	-25.10%	🇺🇸 USA
Abbott Laboratories ABT	23.7	-11.11%	🇺🇸 USA
Eli Lilly LLY	38.4	43.63%	🇺🇸 USA
Sanofi SNY	17.4	-35.02%	🇫🇷 France
Biogen BIIB	21.1	-21.14%	🇺🇸 USA
Merck MRK	33.8	26.54%	🇺🇸 USA
Bristol-Myers Squibb BMY	16.2	-39.51%	🇺🇸 USA
GSK plc GSK	13.3	-50.31%	🇬🇧 UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.